Nasrin Sultana

The NSE MD & CEO helped rebuild the exchange and its reputation after a period riddled with scandals and governance lapses. All eyes are now on the IPO

With the IPO behind them, the fintech platform is widening its playbook—expanding into asset management business, margin trading facilities, commodities and wealth management

Read this exciting story from Forbes India April 17, 2026 issue. As the West Asia war continues to cast a shadow, should you stay invested in stocks?

Read this exciting story from Forbes India April 17, 2026 issue. Atanu Chakraborty's exit at HDFC Bank spotlights the rising stakes and unresolved tensions shaping the role of independent directors in boardrooms

Despite the positive sentiment, the markets’ focus is more on the West Asia conflict and its subsequent fallout on currency, brent crude and corporate earnings

Sun Pharmaceutical’s acquisition of US-based Organon marks a significant repositioning of the company from a largely generics-focussed business to a specialised player

Global brokerage firm Bernstein warns of structural weaknesses while HSBC and JP Morgan downgrade Indian equities. Global uncertainties and domestic stocks will test India’s growth resilience

Questions arise over compliance and transparency as sexual harassment cases at banks and IT companies swell. Experts urge Sebi to re-examine disclosure norms

While the import duty hike on gold and silver is meant to protect the currency’s freefall, it may be not enough to arrest the slide

Sharp slump in prices of Brent crude also fuelled market sentiment, while risks around an expensive domestic currency in India and overall economic growth concerns remain